04.12.16
BeiGene, a clinical-stage biopharma focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has appointed Eric Hedrick as its interim chief medical officer. Current chief medical officer, RuiRong Yuan, will leave the company.
Mr. Hedrick has served as a clinical advisor to BeiGene since June 2015. He was previously chief medical officer at Epizyme, and vice president of oncology development and interim chief medical officer at Pharmacyclics, where he was involved in the development of ibrutinib, the BTK inhibitor currently approved for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia.
“On behalf of the team here at BeiGene I would like to thank Rui for her contributions to the development of our clinical programs and in establishing a solid foundation upon which to build our growing global development organization. We wish her every success in the future,” said John Oyler, chief executive officer, BeiGene. “We have a number of key clinical milestones ahead of us including the start of our registration program for our BTK inhibitor BGB-3111 as well as additional combination trials, and we are on track to report data on each of our clinical candidates this year. Eric’s significant expertise in oncology and hematology and highly relevant prior experiences in the industry make him the ideal choice to oversee and drive our pipeline forward.”
Mr. Hedrick has served as a clinical advisor to BeiGene since June 2015. He was previously chief medical officer at Epizyme, and vice president of oncology development and interim chief medical officer at Pharmacyclics, where he was involved in the development of ibrutinib, the BTK inhibitor currently approved for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia.
“On behalf of the team here at BeiGene I would like to thank Rui for her contributions to the development of our clinical programs and in establishing a solid foundation upon which to build our growing global development organization. We wish her every success in the future,” said John Oyler, chief executive officer, BeiGene. “We have a number of key clinical milestones ahead of us including the start of our registration program for our BTK inhibitor BGB-3111 as well as additional combination trials, and we are on track to report data on each of our clinical candidates this year. Eric’s significant expertise in oncology and hematology and highly relevant prior experiences in the industry make him the ideal choice to oversee and drive our pipeline forward.”